Important Safety Information Prescribing Information Patient Site

About

TREAT NOW WITH THE FIRST FDA-APPROVED THERAPY FOR MOLLUSCUM

FOR AGES
2+

YCANTH®—precise control with proven results1

Photo is illustrative and not representative of all patients.

YCANTH—designed to ensure a consistent treatment experience with a controlled formulation in each applicator1

The innovative applicator contains an ether-free formulation of cantharidin within a sealed glass ampule. YCANTH must be administered by a trained, licensed healthcare professional.2

Applicator Diagram
  1. Small applicator opening allows for targeting of each lesion
  2. A coloring agent helps prevent multiple applications to the same lesion
  3. GMP-controlled, consistent formulation of 0.7% (w/v) cantharidin
  4. Single-use applicator
  5. Prepared by breaking the glass ampule with a YCANTH Break Tool to release YCANTH into the applicator
  6. Contains a bittering agent to help deter ingestion
Applicator Diagram
  1. Small applicator opening allows for targeting of each lesion
  2. A coloring agent helps prevent multiple applications to the same lesion
  3. GMP-controlled, consistent formulation of 0.7% (w/v) cantharidin
  4. Single-use applicator
  5. Prepared by breaking the glass ampule with a YCANTH Break Tool to release YCANTH into the applicator
  6. Contains a bittering agent to help deter ingestion

Applicator is not to scale.

YCANTH is the only FDA-approved formulation of cantharidin2

The FDA warns that compounded copies of an approved product will unnecessarily expose a patient to drug products that have not been shown to be safe and effective. See the FDA guidance here.

Learn how to apply YCANTH for your patients by watching a step-by-step instructional video.

WATCH VIDEO

YCANTH is easily applied in the office

Using the small-tip applicator, apply only enough to cover each lesion2*

  • YCANTH may be administered every 3 weeks, as needed2
  • If YCANTH comes in contact with healthy skin during application, it should be removed with a cotton swab or gauze2
  • Avoid application near the eyes and mucosal tissues, and to adjacent healthy skin2

YCANTH should be removed with soap and water 24 hours after treatment2

  • Do not cover treated lesions with bandages2
  • If severe blistering, severe pain, or other adverse reactions occur, remove YCANTH prior to the recommended 24 hours after administration2

What you should know before administering YCANTH

  • Verrica is committed to providing a training program to ensure an optimal experience
  • Counsel your patients to avoid contact with the treatment areas, including oral contact2
  • YCANTH is flammable; avoid fire, flame, or smoking near lesion(s) during treatment2
  • YCANTH is not for oral, mucosal, or ophthalmic use2

*

YCANTH should be applied only to lesions that are practically and medically safe to treat.2

Applicator

Consistent formulation, precise control.1

In two phase 3 clinical trials, significantly more patients treated with YCANTH achieved complete clearance of new and baseline lesions compared with vehicle within 12 weeks (P<0.0001)1,3

CAMP‑1:  46% vs 18% (P<0.0001)4 CAMP‑2:  54% vs 13% (P<0.0001)4
DISCOVER THE EFFICACY DATA

YCANTH is a vesicant. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH. No serious adverse reactions were reported in clinical trials.2

For additional YCANTH resources:

OFFICE RESOURCES
PATIENT RESOURCES

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.

References: 1. Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(12):1315-1323. doi:10.1001/jamadermatol.2020.3238 2. YCANTH (cantharidin) topical solution 0.7% Prescribing Information, Verrica Pharmaceuticals Inc., 2023. 3. Eichenfield LF, Siegfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating VP-102, a drug-device combination product containing cantharidin 0.7% (w/v) for the treatment of molluscum contagiosum. Am J Clin Dermatol. 2021;22(2):257-265. doi:10.1007/s40257-020-00570-8 4. Data on file. Verrica Pharmaceuticals Inc., 2024.

CAMP‑1/CAMP‑2=Cantharidin Application in Molluscum Patients-1 and -2; FDA=Food and Drug Administration; GMP=good manufacturing practice.